GeoVax Labs (NASDAQ:GOVX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $8.00 target price on the stock.

Several other research analysts also recently commented on GOVX. Alliance Global Partners assumed coverage on shares of GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock. EF Hutton Acquisition Co. I upgraded GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Finally, Noble Financial increased their target price on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, August 19th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $13.25.

GeoVax Labs Stock Performance

Shares of GOVX traded down $0.18 during trading hours on Friday, hitting $2.43. 859,139 shares of the company were exchanged, compared to its average volume of 2,512,010. The firm’s 50 day moving average is $2.37 and its 200-day moving average is $2.60. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same period in the previous year, the company earned ($4.80) EPS. As a group, equities research analysts forecast that GeoVax Labs will post -5.1 earnings per share for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.